The Relationship of Preconception and Early Pregnancy Isoprostanes with Fecundability and Pregnancy Loss.
Journal
Epidemiology (Cambridge, Mass.)
ISSN: 1531-5487
Titre abrégé: Epidemiology
Pays: United States
ID NLM: 9009644
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
pmc-release:
01
09
2024
medline:
3
8
2023
pubmed:
31
5
2023
entrez:
31
5
2023
Statut:
ppublish
Résumé
Although redox stress likely plays an important role in reproductive health, the utility of peripheral biomarkers of oxidative stress, such as isoprostanes, during the periconception period remains underexplored. We evaluated the relationship between isoprostanes during preconception and gestational week 4 and women's reproductive health outcomes. The Effects of Aspirin in Gestation and Reproduction trial (2007-2011) enrolled 1228 women attempting pregnancy and followed them for up to 6 menstrual cycles and throughout pregnancy if they became pregnant. We measured creatinine-adjusted, log-transformed isoprostanes 8-iso-prostaglandin F 2α (8-iso-PGF2α), its metabolite 2,3-dinor-iPF2α-III, and stereoisomers 5-iso-PGF2α-VI and 8,12-iso-iPF2α-VI in urine during preconception and 4 weeks gestation. We evaluated pregnancy among participants in each menstrual cycle using human chorionic gonadotropin (hCG) and defined pregnancy loss as observed loss following positive hCG. We calculated fecundability odds ratios (FOR) and 95% confidence intervals (CI) using discrete-time Cox proportional hazards models and relative risk of pregnancy loss using adjusted log-binomial models. Higher preconception isoprostane levels were associated with lower fecundability [e.g., FOR = 0.89; 95% CI = 0.81, 0.97 per interquartile range (IQR) increase in 8-iso-PGF2α]. Among 797 pregnancies, isoprostane levels increased from preconception to 4 weeks gestation (e.g., mean difference = 0.12; 95% CI = 0.10, 0.14 ng/mL for 8-iso-PGF2α) and higher isoprostanes at 4 weeks gestation were associated with lower risk of pregnancy loss (e.g., RR = 0.79; 95% CI = 0.62, 1.00 per IQR increase in 8-iso-PGF2α). Preconception urinary isoprostanes may identify redox stress pathways associated with lower fecundability. However, the increase in isoprostanes into gestational week 4 and the associated lower risk of pregnancy loss may suggest confounding by latent factors in early pregnancy.
Sections du résumé
BACKGROUND
Although redox stress likely plays an important role in reproductive health, the utility of peripheral biomarkers of oxidative stress, such as isoprostanes, during the periconception period remains underexplored. We evaluated the relationship between isoprostanes during preconception and gestational week 4 and women's reproductive health outcomes.
METHODS
The Effects of Aspirin in Gestation and Reproduction trial (2007-2011) enrolled 1228 women attempting pregnancy and followed them for up to 6 menstrual cycles and throughout pregnancy if they became pregnant. We measured creatinine-adjusted, log-transformed isoprostanes 8-iso-prostaglandin F 2α (8-iso-PGF2α), its metabolite 2,3-dinor-iPF2α-III, and stereoisomers 5-iso-PGF2α-VI and 8,12-iso-iPF2α-VI in urine during preconception and 4 weeks gestation. We evaluated pregnancy among participants in each menstrual cycle using human chorionic gonadotropin (hCG) and defined pregnancy loss as observed loss following positive hCG. We calculated fecundability odds ratios (FOR) and 95% confidence intervals (CI) using discrete-time Cox proportional hazards models and relative risk of pregnancy loss using adjusted log-binomial models.
RESULTS
Higher preconception isoprostane levels were associated with lower fecundability [e.g., FOR = 0.89; 95% CI = 0.81, 0.97 per interquartile range (IQR) increase in 8-iso-PGF2α]. Among 797 pregnancies, isoprostane levels increased from preconception to 4 weeks gestation (e.g., mean difference = 0.12; 95% CI = 0.10, 0.14 ng/mL for 8-iso-PGF2α) and higher isoprostanes at 4 weeks gestation were associated with lower risk of pregnancy loss (e.g., RR = 0.79; 95% CI = 0.62, 1.00 per IQR increase in 8-iso-PGF2α).
CONCLUSIONS
Preconception urinary isoprostanes may identify redox stress pathways associated with lower fecundability. However, the increase in isoprostanes into gestational week 4 and the associated lower risk of pregnancy loss may suggest confounding by latent factors in early pregnancy.
Identifiants
pubmed: 37255247
doi: 10.1097/EDE.0000000000001631
pii: 00001648-990000000-00146
pmc: PMC10525006
mid: NIHMS1903465
doi:
Substances chimiques
Isoprostanes
0
Aspirin
R16CO5Y76E
Banques de données
ClinicalTrials.gov
['NCT00467363']
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
759-766Subventions
Organisme : NIEHS NIH HHS
ID : P30 ES013508
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 HD008795
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA HD008795
Pays : United States
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Free Radic Res. 2004 Feb;38(2):105-22
pubmed: 15104204
J Physiol Pharmacol. 2019 Dec;70(6):
pubmed: 32084643
Free Radic Biol Med. 2005 Jun 1;38(11):1537-41
pubmed: 15890628
Thromb Res. 2003 Jun 15;110(5-6):255-8
pubmed: 14592543
J Lipid Res. 2007 Jul;48(7):1607-17
pubmed: 17456897
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1462-7
pubmed: 21220312
Prostaglandins Other Lipid Mediat. 2018 Jan;134:7-15
pubmed: 29129796
Lancet. 2014 Jul 5;384(9937):29-36
pubmed: 24702835
Free Radic Res. 2004 Sep;38(9):913-8
pubmed: 15621708
Exp Cell Res. 2003 Jul 15;287(2):314-24
pubmed: 12837287
Hum Reprod. 2019 Dec 1;34(12):2399-2409
pubmed: 31887223
Free Radic Biol Med. 2019 Nov 1;143:95-100
pubmed: 31369838
Ann Neurol. 2000 Nov;48(5):809-12
pubmed: 11079549
N Engl J Med. 2004 Feb 12;350(7):672-83
pubmed: 14764923
J Assist Reprod Genet. 2012 Oct;29(10):1083-9
pubmed: 22798064
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Endocrinology. 2011 Feb;152(2):730-40
pubmed: 21159852
Toxics. 2016 Mar;4(1):
pubmed: 28008399
Stat Methods Med Res. 2007 Jun;16(3):219-42
pubmed: 17621469
J Mol Med (Berl). 2013 Mar;91(3):323-8
pubmed: 23430240
Biomed Res Int. 2015;2015:814543
pubmed: 25705690
Am J Clin Nutr. 2010 Dec;92(6):1461-7
pubmed: 20943796
Placenta. 2005 Feb-Mar;26(2-3):114-23
pubmed: 15708112
J Obstet Gynaecol Res. 2019 Feb;45(2):258-265
pubmed: 30328240
Prostaglandins Leukot Essent Fatty Acids. 2019 Jun;145:7-14
pubmed: 31126516
Free Radic Res. 2009 Jun;43(6):546-52
pubmed: 19384749
J Endocr Soc. 2017 Apr 07;1(5):436-448
pubmed: 29264499
Biochim Biophys Acta Mol Basis Dis. 2020 Feb 1;1866(2):165354
pubmed: 30590104
J Clin Endocrinol Metab. 2017 May 1;102(5):1495-1504
pubmed: 28323989
Am J Epidemiol. 2010 Aug 15;172(4):430-9
pubmed: 20679069
Ann N Y Acad Sci. 2011 Mar;1221:80-7
pubmed: 21401634
Int J Biochem Cell Biol. 2010 Oct;42(10):1634-50
pubmed: 20601089
Reprod Biol Endocrinol. 2018 Aug 20;16(1):80
pubmed: 30126412
Int J Hyg Environ Health. 2016 Aug;219(6):545-56
pubmed: 27321041
Curr Environ Health Rep. 2017 Mar;4(1):44-50
pubmed: 28097619
Paediatr Perinat Epidemiol. 2013 Nov;27(6):598-609
pubmed: 24118062
Am J Obstet Gynecol. 2015 Feb;212(2):208.e1-8
pubmed: 25111586
Fertil Steril. 2004 Apr;81(4):973-6
pubmed: 15066450
Endocr Rev. 2009 Aug;30(5):465-93
pubmed: 19589949
Am J Clin Nutr. 2005 Jun;81(6):1390-6
pubmed: 15941892
Placenta. 2007 Apr;28 Suppl A:S133-6
pubmed: 17291583
PLoS One. 2019 Apr 25;14(4):e0215853
pubmed: 31022220
Am J Reprod Immunol. 2018 Oct;80(4):e13017
pubmed: 29984454
Nutr Res. 2015 Jan;35(1):7-13
pubmed: 25453541